Given the prevalence of underlying hematological disorders, it is essential to investigate somatic mutations in the JAK2, including V617F and exon 12 mutations, as well as mutations in the CALR and MPL genes [6,11]. The gene discussed is CALR; the disease is hematologic disorder.